THE CIRCULATORY REGULATION OF TPA AND UPA SECRETION, CLEARANCE, AND INHIBITION DURING EXERCISE AND DURING THE INFUSION OF ISOPROTERENOL AND PHENYLEPHRINE

被引:80
作者
CHANDLER, WL
LEVY, WC
STRATTON, JR
机构
[1] UNIV WASHINGTON, DEPT MED, DIV CARDIOL, SEATTLE, WA 98195 USA
[2] VET ADM MED CTR, SEATTLE, WA USA
关键词
PLASMINOGEN ACTIVATORS; EXERCISE;
D O I
10.1161/01.CIR.92.10.2984
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Exercise to exhaustion and infusions of isoproterenol and phenylephrine were used to study interactions between plasminogen activator regulation and the control of regional blood flow in 10 healthy males. Methods and Results Experimental measurements of cardiac output, heart rate, tissue plasminogen activator (TPA), urokinase plasminogen activator (UPA), plasminogen activator inhibitor (PAI-1), C1-inhibitor, and TPA/C1-inhibitor complex during the infusions and exercise were used to develop a comprehensive fluid-phase model of the circulatory regulation of fibrinolysis. alpha- and beta-adrenergic agonists increased TPA and UPA in plasma by different mechanisms: Phenylephrine decreased hepatic blood flow and thus clearance while isoproterenol stimulated increased secretion of TPA and UPA. Exercise to exhaustion increased TPA and UPA through a combination of increased secretion and decreased clearance. The time course of UPA and TPA release were similar, but the magnitude of their secretion responses differed. In vivo, C1-inhibitor bound to TPA at a rate of 553 mol(-1) . s(-1). C1-inhibitor contributed equally with PAI-1 to TPA inhibition when active PAI-1 levels were low (20 to 50 pmo/L) but was less important when active PAI-1 levels were high. Conclusions We conclude that secretion. inhibition, clearance, and regional blood flow effects must all be taken into account when evaluating changes in plasminogen activator levels.
引用
收藏
页码:2984 / 2994
页数:11
相关论文
共 75 条
[1]  
Hamsten A., Walldius G., Szamosi A., Blombaeck M., De Faire U., Dahlen G., Landou C., Wiman B., Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction, Lancet, 2, pp. 3-9, (1987)
[2]  
Ridker P.M., Vaughan D.E., Stampfer M.J., Manson J.E., Hennekens C.H., Endogenous tissue-type plasminogen activator and risk of myocardial infarction, Lancet, 341, pp. 1165-1168, (1993)
[3]  
Munkvad S., Gram J., Jespersen J., A depression of active tissue plasminogen activator in plasma characterizes patients with unstable angina pectoris who develop myocardial infarction, Eur Heart J, 11, pp. 525-528, (1990)
[4]  
Jansson J.H., Olofsson B.O., Nilsson T.K., Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease, Circulation, 88, pp. 2030-2034, (1993)
[5]  
Gram J., Jespersen J., A selective depression of tissue plasminogen activator (t-PA) activity in euglobulin characterizes a risk group among survivors of acute myocardial infarction, Thromb Haemost, 61, pp. 289-293, (1987)
[6]  
Zalewski A., Shi Y., Nardone D., Bravette B., Weinstock P., Fischman D., Wilson P., Goldberg S., Levin D.C., Bjornsson T.D., Evidence for reduced fibrinolytic activity in unstable angina at rest: Clinical, biochemical, and angiographic correlates, Circulation, 83, pp. 1685-1691, (1991)
[7]  
Cortellaro M., Cofrancesco E., Boschetti C., Mussoni L., Donati M.B., Cardillo M., Catalano M., Gabrielli L., Lombardi B., Specchia G., Tavazzi L., Tremoli E., Pozzoli E., Turri M., Increased fibrin turnover and high PAI-1 activity as predictors of ischemic events in atherosclerotic patients, Arterioscler Thromb, 13, pp. 1412-1417, (1993)
[8]  
Margaglione M., Di Minno G., Grandone E., Vecchione G., Celentano E., Cappucci G., Grilli M., Simone P., Panico S., Mancini M., Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke, Arterioscler Thromb, 14, pp. 1741-1745, (1994)
[9]  
Kluft C., Constitutive synthesis of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1): Conditions and therapeutic targets, Fibrinolysis, 8, 2 SUPPL., pp. 1-7, (1994)
[10]  
Emeis J.J., Mechanisms involved in short-term changes in blood levels of t-PA, Tissue-type Plasminogen Activator (T-PA): Physiological and Clinical Aspects, pp. 21-36, (1988)